Metabolic Modifiers and Surveillance Strategies in HBV: Epidemiologic Insights and Global Elimination Goals

Nov 09 2025
Convention Center: Ballroom A, Level 3
2:00 PM - 3:30 PM

World Class Speakers

Robert J Wong, MD
Abstract Presenter

Robert J Wong, MD

Stanford/VA Palo Alto Healthcare System
JJ
Abstract Presenter

Janice Jou, MD, MHS, FAASLD

VA Portland Healthcare System/OHSU
Adnan Said, MD, MS, FAASLD
Abstract Presenter

Adnan Said, MD, MS, FAASLD

University of Wisconsin School of Medicine and Public Health
JJ
Moderator

Janice Jou, MD, MHS, FAASLD

VA Portland Healthcare System/OHSU
Adnan Said, MD, MS, FAASLD
Moderator

Adnan Said, MD, MS, FAASLD

University of Wisconsin School of Medicine and Public Health

Description

This session will examine the intersection of chronic hepatitis B with metabolic risk factors, pharmacologic exposures, and evolving biomarkers in liver disease progression and surveillance. Topics will include the protective association of statins with HCC risk, the impact of hepatitis B on fibrosis in MASLD and the impact of GLP-1 on outcomes in HBV. Additional talks will address the potential for HBsAg quantification to define thresholds for discontinuing HCC surveillance and global progress toward HBV elimination targets.

Journey Maps

Presentations

3:00 PM - 3:15 PM
May 18 2026
Washington, D.C.

Hepatocellular Carcinoma Risk Between Untreated Immune Tolerant vs. Treated Immune Active Chronic Hepatitis B Patients: A Longitudinal Analysis of National Veterans Affairs Cohort

Robert J Wong, MD , Abstract Presenter
Hepatitis
Liver Cancer
MASLD
2:15 PM - 2:30 PM
May 18 2026
Washington, D.C.

The Impact of Chronic Hepatitis B and Its Clinical Phases on significant liver fibrosis in Metabolic Dysfunction-Associated Steatotic Liver Disease

Janice Jou, MD, MHS, FAASLD , Abstract Presenter
Hepatitis
Liver Cancer
MASLD
2:30 PM - 2:45 PM
May 18 2026
Washington, D.C.

Glucose-like peptide-1 receptor agonists and reduced liver and non-liver complications in patients with type 2 diabetes and viral hepatitis

Adnan Said, MD, MS, FAASLD , Abstract Presenter
Hepatitis
Liver Cancer
MASLD

Objectives

  • Evaluate the impact of statins and MASLD on HBV disease progression and hepatocellular carcinoma risk
  • Assess how HBsAg quantification and metabolic comorbidities such as MASLD may refine fibrosis staging and HCC surveillance decisions in chronic HBV
  • Describe current epidemiologic trends and global efforts toward HBV elimination, including implications for surveillance and care strategies in diverse populations